Prometheus Biosciences Inc.

12/07/2021 | Press release | Distributed by Public on 12/07/2021 06:02

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial[...]